Why the study?
Diabetes and cardiac hypertrophy are closely interconnected via overlapping metabolic and cardiovascular pathways, requiring an investigation into the underlying mechanisms and an evaluation of diagnostic and therapeutic strategies.
Design
Literature review
Key result
Diabetes significantly contributes to the progression of cardiac hypertrophy through metabolic dysregulation and persistent low-grade inflammation, necessitating integrated diagnostic and therapeutic approaches.
Authors
Loading...
Warrants vigilance for hypertrophy in diabetes without practice change; extends pathway knowledge but leaves optimal strategies unresolved.
The robust association between diabetes and cardiac hypertrophy underscores the necessity for an integrated approach combining early detection with targeted pharmacotherapy such as SGLT2 inhibitors and GLP-1 receptor agonists.
Joshi et al. (2026) conducted a review in Diabetes mellitus and cardiac hypertrophy. Diabetes significantly contributes to the progression of cardiac hypertrophy through metabolic dysregulation and persistent low-grade inflammation, necessitating integrated diagnostic and therapeutic approaches.